



# MOREPEN



**Date: 31/08/2020**

To,

**National Stock Exchange of India Ltd.**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051

Tel No: (022) 26598100 - 8114

Fax No: (022) 26598120

**Symbol: MOREPENLAB**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400 001

Phones: 91-22-22721233/4

Fax: 91-22-2272 3121

**Scrip Code: 500288**

**Subject: Outcome of the meeting of the Board of Directors of the Company**

Dear Sir/ Madam,

This is to inform you that the Board of Directors of the Company, in their meeting held on Monday, 31<sup>st</sup> August, 2020 (*commenced at 12.00 Noon and concluded at 01.30 P.M.*), have, *inter-alia*, considered and approved

- (1) The unaudited standalone and consolidated financial results of the Company for the quarter ended 30<sup>th</sup> June, 2020, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

A copy of the 'Results' along-with the 'Limited Review Report' of the Auditors of the Company for the quarter ended 30<sup>th</sup> June, 2020 is enclosed herewith.

- (2) Expansion of APIs (bulk drugs) manufacturing capacity.

A copy of disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, as amended, is enclosed herewith as **Annexure-A**.

Kindly acknowledge the receipt and take it on your record.

Thanking you.

Yours faithfully,

**For Morepen Laboratories Limited**

  
(Vipul Kumar Srivastava)  
Company Secretary

*Encl.: As above*

**Morepen Laboratories Limited**

**Corp. Off.:** 4th Floor, Antriksh Bhawan, 22 K.G.Marg, New Delhi- 110 001, INDIA  
Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: www.morepen.com  
CIN NO. L24231 HP1984PLC006028

**Plant & Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205  
Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com

**Morepen Laboratories Limited**  
CIN- L24231HP1984PLC006028  
**Statement of Unaudited Financial Results - Standalone**  
**For the Quarter Ended 30th June, 2020**

(Rs. in Lakhs)

	Quarter Ended			Year Ended
	30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
<b>Particulars</b>				
<b>1. Revenue</b>				
Revenue from operations (Net)	24325.84	18915.12	18946.51	79198.74
Other Income	132.88	172.15	28.14	941.72
<b>Total Revenue</b>	<b>24458.72</b>	<b>19087.27</b>	<b>18974.65</b>	<b>80140.46</b>
<b>2. Expenditure</b>				
a) Cost of Material Consumed	13315.30	7142.63	10359.60	41321.87
b) Purchase of stock - in - trade	3125.19	2060.98	2298.14	11545.31
c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	(80.42)	2328.85	(93.81)	(758.40)
d) Employee Benefits Expenses	2667.48	2752.80	2125.21	9807.19
e) Finance Cost	28.74	62.02	42.13	196.75
f) Depreciation and Amortization	746.98	797.08	1089.74	3443.39
g) Power and Fuel	241.55	287.83	304.04	1255.79
h) Travelling Expenses	197.18	262.61	225.15	1045.96
i) Selling and Distribution Expenses	944.35	856.87	922.91	3575.37
j) Other Expenses	1387.70	1587.78	860.76	4959.05
<b>Total Expenditure</b>	<b>22574.05</b>	<b>18139.45</b>	<b>18133.87</b>	<b>76392.28</b>
<b>3. Profit before Tax (1-2)</b>	<b>1884.67</b>	<b>947.82</b>	<b>840.78</b>	<b>3748.18</b>
<b>4. Tax Expense</b>				
Tax	-	-	(183.85)	-
Tax Credit Entitlements	-	-	183.85	-
Income Tax - Earlier period	-	-	-	(514.87)
<b>Total Tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(514.87)</b>
<b>5. Net Profit for the period (3-4)</b>	<b>1884.67</b>	<b>947.82</b>	<b>840.78</b>	<b>3233.31</b>
<b>6. Other Comprehensive Income (OCI)</b>				
Items that will not be reclassified to Profit & Loss	90.54	(79.31)	9.48	(217.25)
Tax Expense	-	-	(2.04)	-
Tax Credit Entitlements	-	-	2.04	-
Income Tax - Earlier period	-	-	-	(37.03)
<b>Total Other Comprehensive Income (Net of Tax)</b>	<b>90.54</b>	<b>(79.31)</b>	<b>9.48</b>	<b>(254.28)</b>
<b>7. Total Comprehensive Income</b>	<b>1975.21</b>	<b>868.51</b>	<b>850.26</b>	<b>2979.03</b>
<b>8. Paid-up Equity Share Capital of Face Value of Rs. 2/- each</b>	<b>8995.86</b>	<b>8995.86</b>	<b>8995.86</b>	<b>8995.86</b>
<b>9. Reserves excluding Revaluation Reserve</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>21728.83</b>
<b>10. Earning Per Share (in Rs.) -</b>				
Basic & Diluted	0.42	0.21	0.19	0.72

**Notes :**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 31, 2020. A Limited review of the same has been carried out by the Statutory Auditors.
- The Company is engaged in the Pharmaceutical Business Segment.
- Figures of the quarter ended March 31, 2020 are the balancing figures between audited figures in respect of the full financial year and the year to date figure up to the third quarter of the relevant financial year which were subjected to Limited Review by the Auditors.
- The company continues to monitor the impact of Covid-19 on its operations, supply chain and recoverability of carrying amounts for the financial and non-financial assets. Due care has been taken, in applying significant accounting judgements and estimates, including in relation to recoverability of receivables and inventory, in preparing the company's financial results for the quarter ended June 30, 2020. However, as the impact assessment of Covid-19 is a continuing process, the company will continue to monitor any material changes to future economic conditions.

For and on behalf of the Board of Directors

Place : New Delhi  
Date : August 31, 2020



(Sushil Suri)  
Chairman & Managing Director




**Satinder Goyal & Co.**  
**Chartered Accountants**

---

**Limited Review Report – Standalone Financial Results**

**Review Report to  
The Board of Directors  
Morepen Laboratories Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results of Morepen Laboratories Limited (the “Company”) for the quarter ended June 30, 2020 (the “Statement”), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the quarter ended March 31, 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the previous financial year, which were subject to limited review by us.



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Date : 31<sup>st</sup> August 2020  
Place : New Delhi

For Satinder Goyal & Co.  
Chartered Accountants  
Firm's Regn. No: 027334N

CA S.K Goyal  
(Partner)  
Membership No. : 084613  
UDIN : 20084613AAAAAQ2983

**Morepen Laboratories Limited**  
CIN- L24231HP1984PLC006028  
**Statement of Unaudited Financial Results - Consolidated**  
**For the Quarter Ended 30th June, 2020**

(Rs. in Lakhs)

	Particulars	Quarter Ended			Year Ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	<b>Revenue</b>				
	Revenue from operations (Net)	25764.24	20660.26	20298.12	85306.69
	Other Income	132.88	178.48	28.14	948.35
	<b>Total Revenue</b>	<b>25897.12</b>	<b>20838.74</b>	<b>20326.26</b>	<b>86255.04</b>
2.	<b>Expenditure</b>				
	a) Cost of Material Consumed	13315.30	7142.63	10359.60	41321.87
	b) Purchase of stock - in - trade	4134.15	3398.09	3092.15	15442.69
	c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	(171.71)	2066.15	(37.80)	(1022.71)
	d) Employee Benefits Expenses	2947.95	3020.81	2420.47	10990.60
	e) Finance Cost	28.77	62.22	42.77	198.45
	f) Depreciation and Amortization	805.76	862.61	1150.30	3690.60
	g) Power and Fuel	241.55	287.83	304.04	1255.79
	h) Travelling Expenses	244.46	337.24	306.21	1383.17
	i) Selling and Distribution Expenses	1065.81	900.53	979.72	3857.69
	j) Other Expenses	1329.58	1624.36	940.77	5226.13
	<b>Total Expenditure</b>	<b>23941.62</b>	<b>19702.47</b>	<b>19558.23</b>	<b>82344.28</b>
3.	<b>Profit before Tax (1-2)</b>	<b>1955.50</b>	<b>1136.27</b>	<b>768.03</b>	<b>3910.76</b>
4.	<b>Tax Expense</b>				
	Tax	(18.79)	(33.56)	(185.98)	(37.40)
	Tax Credit Entitlements	-	-	183.85	-
	Income Tax - Earlier period	-	(0.60)	-	(515.47)
	<b>Total Tax</b>	<b>(18.79)</b>	<b>(34.16)</b>	<b>(2.13)</b>	<b>(552.87)</b>
5.	<b>Net Profit for the period (3-4)</b>	<b>1936.71</b>	<b>1102.11</b>	<b>765.90</b>	<b>3357.89</b>
6.	Share of Minority Interest in Profit/ (Loss)	(0.02)	0.02	(0.02)	(0.03)
7.	<b>Net Profit after after Minority Interest</b>	<b>1936.73</b>	<b>1102.09</b>	<b>765.92</b>	<b>3357.92</b>
8.	<b>Other Comprehensive Income (OCI)</b>				
	Items that will not be reclassified to Profit & Loss	94.69	(82.19)	5.63	(226.35)
	Tax Expense	(1.04)	2.29	(2.04)	2.29
	Tax Credit Entitlements	-	-	2.04	-
	Income Tax - Earlier period	-	-	-	(37.03)
	<b>Total Other Comprehensive Income (Net of Tax)</b>	<b>93.65</b>	<b>(79.90)</b>	<b>5.63</b>	<b>(261.09)</b>
9.	<b>Total Comprehensive Income</b>	<b>2030.38</b>	<b>1022.19</b>	<b>771.55</b>	<b>3096.83</b>
10.	Paid-up Equity Share Capital of Face Value of Rs. 2/- each	8995.86	8995.86	8995.86	8995.86
11.	Reserves excluding Revaluation Reserve	-	-	-	19410.25
12.	Earning Per Share (in Rs.) -				
	Basic & Diluted	0.43	0.25	0.17	0.75

**Notes :**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 31, 2020. A Limited review of the same has been carried out by the Statutory Auditors.
- The Company is engaged in the Pharmaceutical Business Segment.
- Figures of the quarter ended March 31, 2020 are the balancing figures between audited figures in respect of the full financial year and the year to date figure up to the third quarter of the relevant financial year which were subjected to Limited Review by the Auditors.
- The company continues to monitor the impact of Covid-19 on its operations, supply chain and recoverability of carrying amounts for the financial and non-financial assets. Due care has been taken, in applying significant accounting judgements and estimates, including in relation to recoverability of receivables and inventory, in preparing the company's financial results for the quarter ended June 30, 2020. However, as the impact assessment of Covid-19 is a continuing process, the company will continue to monitor any material changes to future economic conditions.

For and on behalf of the Board of Directors

Place : New Delhi  
Date : August 31, 2020



Sushi Suri  
(Sushi Suri)  
Chairman & Managing Director





506, Ambadeep Building, 14, K.G. Marg  
New Delhi-110001 Ph. 011-49425734  
mail : satindergoyalandco@gmail.com

**Satinder Goyal & Co.**  
**Chartered Accountants**

---

**Limited Review Report – Consolidated Financial Results**

**Review Report to  
The Board of Directors  
Morepen Laboratories Limited**

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Morepen Laboratories Limited (the “Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as the “Group”) for the quarter ended June 30, 2020 (the “Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. This Statement includes the results of the following Group entities:

- Morepen Laboratories Limited (the "Parent")
- Dr. Morepen Limited (Indian Subsidiary)
- Total Care Limited (Indian Subsidiary)
- Morepen Inc. (Foreign Subsidiary)

5. The consolidated unaudited financial results includes the interim financial results of Morepen Inc., a foreign subsidiary which have not been reviewed/audited by their auditors, whose interim financial results reflect total comprehensive Income of Rs. 19.24 lakhs (comprising of total revenue of Rs. 30.56 lakhs and total expenses of Rs. 11.32 lakhs) for the quarter ended June 30, 2020. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

We have also not reviewed the financial results of above stated foreign subsidiary considered in the preparation of the Statement. These financial results have been furnished to us by the management.

Our conclusion on the Statement is not modified in respect of the above matter.

6. Attention is drawn to the fact that the figures for the quarter ended March 31, 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the previous financial year, which were subject to limited review by us.

7. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Date : 31<sup>st</sup> August 2020  
Place : New Delhi

For Satinder Goyal & Co.  
Chartered Accountants  
Firm's Regn. No: 027334N

CA S.K Goyal  
(Partner)

Membership No. : 084613

UDIN : 20084613AAAAAR7052

**Annexure-A**

**Disclosure pursuant to Schedule III, Para A, Para – B of SEBI (LODR), Regulations, 2015, as amended read with SEBI circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015.**

S. no.	Particulars	Clarification
1.	Existing Capacity, utilisation & proposed capacity addition	It would add 2000 MT per annum of APIs manufacturing capacity in addition to 3000 MT per annum capacity already installed.  The capacity utilisation for existing products at Baddi, API Plant is between 70-80%.
2.	Period within which the Proposed capacity is to be added	The expanded capacity is likely to commence commercial production over the next 3 years.
3	Investment required	The total investment required to for expansion is approx. Rs. 178 Crores.
4.	Mode of financing	Primarily through internal accruals.
5.	Rationale	The relationale behind expansion of APIs manufacturing capacity to become a global sourcing hub for several bulk drugs and to derive benefits of synergies.



**Morepen Laboratories Limited**

**Corp. Off.:** 4th Floor, Antriksh Bhawan, 22 K.G.Marg, New Delhi- 110 001, INDIA  
 Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: www.morepen.com  
 CIN NO. L24231 HP1984PLC006028

**Plant & Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205  
 Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com